Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT01946529
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Armando Santoro, MD
- Target Recruit Count
- 24
- Registration Number
- NCT01884428
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, MI, Italy
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 92
- Registration Number
- NCT01873326
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
- Conditions
- Interventions
- Drug: VincristineDrug: DactinomycinDrug: CyclophosphamideProcedure: Surgical ResectionProcedure: RadiationDrug: Myeloid Growth FactorDrug: BevacizumabProcedure: Lymph Node SamplingDrug: SorafenibDrug: ^1^1C-methionineDrug: IrinotecanDrug: IfosfamideDrug: EtoposideDrug: Etoposide PhosphateDrug: DoxorubicinDrug: Dexrazoxane
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT01871766
- Locations
- 🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸University of Florida Proton Therapy Institute, Jacksonville, Florida, United States
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT01864109
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
- Conditions
- Recurrent Childhood Supratentorial Primitive Neuroectodermal TumorEwing Sarcoma of BoneMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorAdult Supratentorial Primitive Neuroectodermal Tumor (PNET)Extraosseous Ewing SarcomaUntreated Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- Drug: etoposideDrug: ifosfamideRadiation: intensity-modulated radiation therapyDrug: topotecan hydrochlorideDrug: busulfanDrug: melphalanProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationProcedure: autologous bone marrow transplantation
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT01795430
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 262
- Registration Number
- NCT01602666
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
- Conditions
- Recurrent Hepatosplenic T-Cell LymphomaMycosis FungoidesRecurrent Anaplastic Large Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Hepatosplenic T-Cell LymphomaRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Anaplastic Large Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Enteropathy-Associated T-Cell Lymphoma
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT01590732
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 44
- Registration Number
- NCT01505569
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01490060
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.